NanoViricides Inc. (NNVC)

[Raffis]

NNVC IS A WINNER! THEY GENIUSLY REPLICATED HOST RECEPTORS TO BIND AND KILL THE VIRUS IN A COUNTER ATTACK. THIS APPROACH WORKED IN PRECLINICAL STUDY AND IT WILL WORK IN HUMAN TRIALS, BECAUSE THE CAPSULE DID BIND WITH COVID. THE PRECLINICAL RAT STUDY PROVED THAT THE RECEPTOR SITES MATCH. REMDESIVIR IS ALREADY FDA APPROVED. THIS IS A WINNER BECAUSE IT FOCUSES ON RECEPTOR ACTIVATION. AND THE RECEPTORS MATCHED. COVID BINDED TO THE DRUG. THEY ALREADY SUCCEEDED.

https://www.benzinga.com/node/23025282

https://m.benzinga.com/article/19937727?utm_referrer=https%3A%2F%2Fm.benzinga.com%2Farticle%2F22925012%3Futm_referrer%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282%26utm_source%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282&utm_source=https%3A%2F%2Fm.benzinga.com%2Farticle%2F22925012%3Futm_referrer%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282%26utm_source%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282

The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-ß-cyclodextrin sodium salt (SBECD), during the first day of dosing.

Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
The increased intact circulating level did not increase toxicity.

These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.